^
    1d
    SuRage-EB: Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib (clinicaltrials.gov)
    P4, N=0, Withdrawn, SRH Wald-Klinikum Gera GmbH | N=101 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    2d
    Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study. (PubMed, Pediatr Blood Cancer)
    Higher selumetinib exposure appears to be associated with treatment-related adverse effects in pediatric NF1 patients. These findings support the potential role of TDM in optimizing selumetinib dosing and provide a preliminary therapeutic AUC range for individualized treatment strategies. Larger multicenter studies are needed to validate these results and refine exposure-guided dosing approaches.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    Koselugo (selumetinib)
    2d
    A Study of Mirdametinib in People With Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    NF1 (Neurofibromin 1)
    |
    MSK-IMPACT
    |
    Gomekli (mirdametinib)
    3d
    Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer. (PubMed, Int J Gynecol Cancer)
    The authors discuss adverse event management and the implications for integration into routine clinical practice. Clinicians caring for patients with low-grade serous ovarian carcinoma can use the drug knowledge and evidence outlined in this review to assist with implementing avutometinib and defactinib therapy.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    4d
    Impact of Selumetinib on Long-Term Pain Medication Utilization in Pediatric Patients: A Retrospective US Claims Database Study. (PubMed, Pain Ther)
    Selumetinib treatment was associated with a significant, consistent, and durable decline in prescription pain medication utilization over 3 years. Patients who continued taking pain medications experienced nominal dose reductions, and patients who received selumetinib continuously experienced a decrease in prescription pain medication utilization.
    Retrospective data • Journal
    |
    NF1 (Neurofibromin 1)
    |
    Koselugo (selumetinib)
    5d
    InCITe: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=145, Active, not recruiting, Laura Huppert, MD, BA | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    7d
    Multiplex organoid mutagenesis reveals gene combinations driving transformation, pathology and chemosensitivity in ovarian carcinoma. (PubMed, Genetics)
    Map2k4 mutant cells were particularly sensitive to paclitaxel, and Rho kinase inhibitor (ROCKi) increased trametinib sensitivity in both Map2k4- and Nf1-mutant organoids. This organoid mutagenesis strategy is powerful for unraveling the genetic and phenotypic complexity of HGSC, and identified Map2k4 as a potential therapeutic target in select HGSC cases.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
    |
    TP53 mutation
    |
    Mekinist (trametinib) • paclitaxel
    7d
    Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    8d
    Repurposing Ilaprazole as a PP5 TPR Domain Binder with Modulatory Effects on MAPK Signaling. (PubMed, ACS Med Chem Lett)
    While exhibiting minimal single-agent effects, ilaprazole sensitized cells to the MEK inhibitor binimetinib. These results validate the PP5 TPR domain as a druggable site and establish ilaprazole as a lead scaffold for pharmacological modulation of PP5-associated MAPK signaling.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mektovi (binimetinib)
    9d
    PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Terminated, Cancer Trials Ireland | Trial completion date: Jun 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Mar 2026; Study terminated due to futility
    Trial completion date • Trial termination • Trial primary completion date
    |
    Mekinist (trametinib) • hydroxychloroquine
    9d
    Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) (clinicaltrials.gov)
    P1, N=50, Suspended, University of California, San Francisco | Recruiting --> Suspended
    Trial suspension
    |
    Mekinist (trametinib) • everolimus
    9d
    CA209-73R: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Providence Health & Services | Trial completion date: Jan 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)